This issue starts with a Commentary by Lam\[[@B1]\] about the Special Article by Paul Bebbington published in a previous issue.\[[@B2]\] Bebbington's article discussed a new model for conceptualizing psychosis based on findings in psychosocial epidemiology; Lam agrees that this new integrated approach raises the exciting possibility of new methods for preventing the onset of psychosis or ameliorating the course of psychotic disorders, but she cautions much more research will be needed before these potential benefits can be realized.

The meta-analysis by WZ Wang and colleagues\[[@B3]\] reports on the adjunctive use of electroconvulsive therapy (ECT) in the management of treatmentrefractory patients with schizophrenia. Concerns about potential adverse effect of ECT in Western countries has restricted the use of ECT both in the treatment of severe depression and in the treatment of treatmentresistant schizophrenia, so it is not surprising that 18 of the 22 randomized controlled trials about the use of ECT in schizophrenia identified after an extensive search of both the English-language and Chineselanguage literature were conducted in China. The meta-analysis found that combined treatment with ECT and antipsychotic medication had a significantly better outcome than treatment with antipsychotic medication alone. The proportion of participants experiencing headache or cognitive impairment during the treatment was higher in the combined treatment group, but the overall level of functioning at the end of the trial was better in the combined treatment group. The results support the adjunctive use of ECT in treatment-refractory schizophrenia, but the incomplete methodological information provided by most of the included studies from China leaves unanswered questions about the validity of the results, so betterdesigned studies will be needed to confirm these findings.

The first original research article by Zhang and colleagues\[[@B4]\] is about the use of a Japanese-based cognitive therapy-Naikan therapy-as an adjunctive treatment during the recovery phase of schizophrenia. This is a randomized controlled trial (RCT) among 235 inpatients with schizophrenia whose acute symptoms had resolved. Both groups received standard medications and inpatient rehabilitation training; the intervention group was also trained in a cognitive selfreflection process (Naikan therapy) and engaged in this method for 20 2-hour sessions over a 4-week period. All patients were subsequently discharged and followedup 1 year later. Both at the end of the 4-week treatment period and one year after the finish of treatment the severity of symptoms was significantly less and the social functioning was significantly better in the Naikan group than in the control group. The relapse rate over the 1-year follow-up in the Naikan group was half of that in the control group (10.6% v. 20.5%).Given the relatively large sample, the randomized design, and the one-year post-intervention follow-up, this is an impressive finding that deserves to be replicated and, if replicable, widely promoted as an adjunctive treatment in the management of chronic schizophrenia.

The second original research article by ZY Wang and colleagues\[[@B5]\] is the drug pre-registration study in China for generic duloxetine, currently one of the most popular antidepressants in the country. It is a large (n=299), multi-center, double-blind, 8-week RCT that compared generic duloxetine to paroxetine in the treatment of major depressive disorder (MDD). Based on an intention-to-treat (ITT) analysis, there were substantial reductions in the severity of depressive symptoms (assessed using the Hamilton Depression rating scale) in both groups over the 8 weeks of treatment, but no significant differences in the magnitude or rate of improvement between the two groups. The prevalence of mild-to-moderate adverse effects were relatively common (57% in the duloxetine group and 55% in the paroxetine group), but they were severe enough to require discontinuing the treatment in only six patients in each group. The authors conclude that generic duloxetine is effective and safe in the acute treatment of MDD.

The third original research article by SL Wang and colleagues\[[@B6]\] provides information relevant to the ongoing debate about the potential value of a positive family history of affective disorder in predicting the efficacy of different types of antidepressant medication.\[[@B7],[@B8],[@B9]\] The authors enrolled 77 patients with depression (based on the International Classification of Diseases \[ICD-10\] criteria), assessed the status of all first-degree relatives to classify 37 of the patients into a 'positive family history' group and 40 onto a 'no family history' group, and then treated them all with standard doses of duloxetine for 12 weeks. There were several differences between patients with and without a positive family history: those with a positive family history had an earlier age of onset, a longer duration of illness, a higher level of psychic anxiety, and more prominent anhedonia. However, there was no significant difference in the magnitude or rate of improvement of depressive symptoms over the 12 weeks of treatment between patients with and without a positive family history. Treatment met the pre-determined criteria for effectiveness in 76% of patients with a positive family history and 78% of those without a family history. Thus the results do not support hypotheses about the differential effectiveness of medication based on family history of affective disorder.

The Forum pieces by Peng and Jiang\[[@B10]\] and Shi\[[@B11]\] discuss the concurrent occurrence of bipolar and obsessive-compulsive symptoms, a condition that has received increasing attention as more nosologists, researchers, and clinicians consider the etiology and management of comorbid psychiatric conditions.\[[@B12]\] Several lines of research indicate that individuals with comorbid bipolar disorder (BD) and obsessive compulsive disorder (OCD) are different from those with BD in the absence of OCD. There is continuing controversy about whether the concurrent occurrence of these two conditions should be considered a) independent comorbid conditions, b) a relatively severe subtype of BD, or c) a unique condition etiologically distinct from both BD and OCD. The available studies are primarily crosssectional studies with small samples, so they are unable to definitively resolve this issue. Treatment of this comorbid condition can be complicated because using selective serotonin reuptake inhibitors (SSRIs) to treat the OCD may increase the risk of precipitating manic symptoms. This is one of several examples of common comorbid psychiatric disorders (e.g., depression and anxiety) that weaken confidence in the distinctness of the conditions defined in current diagnostic systems. Whether or not the long-prophesied biologic-genetic revolution in diagnostic nosology will eventually resolve these issues remains to be seen.

The case report by Sachdeva and colleagues\[[@B13]\] also considers a comorbid condition, in this case, comorbid schizophrenia and obsessive compulsive disorder. The report presents the case of a patient with a 4-year history of food refusal with severe, disabling obsessive-compulsive symptoms who was initially treated by local non-psychiatric clinicians by tubefeeding and subsequently tube-fed by family members for 4 years prior to his first arrival at a psychiatric clinic. Despite the primary presentation of obsessive compulsive symptoms and food refusal, it subsequently became clear that there was underlying delusions of contamination and substantial formal thought disorder, so the initial diagnosis of obsessive compulsive disorder was subsequently changed to schizophrenia. Treatment with antipsychotic medication combined with behavioral management of the eating behavior (and counselling with family members who were reluctant to stop the tube-feeding because they believed the patient would starve) led to significant improvement in his symptoms, though he remained disabled by his schizophrenia. This case highlights the importance of clarifying the underlying etiology of food refusal, one of several relatively common symptoms that can be the presenting symptom for a variety of psychiatric and medical conditions.

The Biostatistics in Psychiatry article in this issue by Liu\[[@B14]\] provides an introduction to the analysis of longitudinal data sets, a problem that has confounded psychiatric researchers for decades. In psychiatric research this usually involves multiple observations of the same group of individuals at a limited number of time points with equally or unequally spaced intervals. Traditionally researchers used 'multivariate data structures' (with rows representing individuals and columns representing results at different times) to analyze such data, but there are several problems with arranging the data in this way (e.g., time intervals may vary between subjects, and some predictor covariates like economic status or location of residence may vary over time). More recently analysts prefer to use 'univariate data structures' (with each row representing a time at which the outcome is assessed) because this allows time to be explicitly specified as a predictor of the trajectory of individuals. To avoid the often substantial biases that can arise in the analysis of longitudinal data, psychiatric researchers need to familiarize themselves with these newer, more advanced statistical methods.
